VIR.O (VIR.O) News
Follow VIR.O (VIR.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Oct 14 (Reuters) — Vir Biotechnology said on Wednesday it had signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop new cancer treatments for solid tumors. Shares of Vir
EQUITY | Oct 14, 2026, 01:21 PM UTC
L
BUZZ — Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
* Shares of Vir Biotechnology rise 11.7% to $11.85 premarket * Co inks collaboration and license agreement with Gilead for three candidates targeting selected solid tumor-associated antigens * VIR will be eligible to rec
EQUITY | Oct 14, 2026, 12:56 PM UTC
L
Vir Biotechnology partners with Gilead to develop PRO — XTEN dual — masked T — cell engagers for solid tumors
Vir Biotechnology struck a collaboration and license deal with Gilead to discover three dual-masked T-cell engager candidates for solid tumors. Gilead gets exclusive rights to nominate, develop, manufacture, and commerci
NEWS | Oct 14, 2026, 12:32 PM UTC
H
Vir Biotechnology Enters Multi — Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO — XTEN® Dual — masked T — cell Engagers for Solid Tumors
For best results when printing this announcement, please click on link below: Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN(®) Dual
EARNINGS | Oct 14, 2026, 12:31 PM UTC